Clinical Trial Update: A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study comparing Nanvuranlat to physician's best choice in adults with biliary tract cancer; recruitment is ongoin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Nanvuranlat (Nanvuranlat)

Snippet

Sponsor: J-Pharma Co., Ltd. | Conditions: Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | Phase 3 | Status: RECRUITING